Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
Evoke Pharma, Inc. (EVOK)
Last evoke pharma, inc. earnings: 11/7 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
evokepharmainc.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer. “Working closely with Dave has been an absolute privilege,” said Matt D’Onofrio, incoming Chief Executive Officer of Evoke Pharma. “His relentless leadership resulted in our company developing and launching a highly unique and impactful therapy for patients suffering from diabetic gastroparesis. As CEO, I am driven by the same commitment to our core mission to bring GIMOTI to more and more patients who suffer from this devastating disease. Our strategy remains unaltered and our commercial team rem
Show less
Read more
Impact Snapshot
Event Time:
EVOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVOK alerts
High impacting Evoke Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
EVOK
News
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsGlobeNewswire
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EVOK
Sec Filings
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- EVOK's page on the SEC website